The executive team and employees of Midatech represent a unique set of complementary competences, know-how and skill-sets in the life science industry. They have excellent senior executive track records in the global, pharmaceutical and biotech industry.
Dr Jim Phillips, MB., ChB., MBA
Chief Executive Officer
Dr Phillips has a strong background in company leadership and business development. Jim Founded Talisker Pharma in 2004, which was the first and cornerstone acquisition of EUSA Pharma in 2006, as President Europe and Senior Vice President Corporate Development of EUSA Pharma Inc., Dr Phillips then led the strategy resulting in the acquisition of OPI and its ultimate acquisition by Jazz Pharmaceuticals in 2012. Jim has held a number of Board Directorships including Laurantis Pharma OY, Insense Ltd and until joining Midatech was Chairman of Prosonix Limited, guiding its successful transformation into a respiratory-focused business.
Dr Phillips initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. At Novartis, Jim was in Clinical & Business Development, and was Board Director of the AGBHI $1.3bn business unit and a member of the company’s Clinical Leadership Team. He is a Physician by training.
Professor Thomas Rademacher, MD., PhD
President and Chief Scientific Officer
Professor Rademacher is co-founder and currently President and CSO of Midatech. He was CEO and Chairman of the Board of Directors of Midatech from 2000-2013. Prof. Rademacher was co-founder of the Glycobiology Institute at Oxford University and also co-founder of Oxford GlycoSciences plc. He has a Medical Degree and PhD in Biochemistry and is Emeritus Professor of Molecular Medicine at University College London. He has over 250 patents and academic publications and, with nearly 5,000 citations to his work, is in the top 2.5% of cited researchers. Midatech was founded in 2000 as spin-out from technology developed by Professor Soledad Penedes of the Spanish Research Council and colleagues at the CSIC-Seville.
Dr Craig Cook, MD, MBA
Chief Operating Officer / Chief Medical Officer
Dr Cook has more than 20 years of international experience in the pharma, biomedical and high technology sectors including roles across a range of therapeutic areas, such as CNS, inflammatory, immunology, and endocrine, covering both drug development and medical affairs. He has founded and/or led several healthcare ventures including SpaceCode Healthcare Technologies, Sedation Solutions partnership, and SwissCare Health care group. He is advisor lead for Ippon Capital’s life sciences practice. Previous appointments also include executive positions at Serono Biotech, Novartis Pharma, Eli Lilly and Johnson & Johnson. Dr Cook is a qualified physician, has a B.Sc. in Pharmacology, Diploma in Anaesthesiology, and M.B.A. from the London Business School. He joined Midatech in 2014 after concluding the Ippon Capital investment round.
Justin Barry, BSc Hons., Mbiol., CBiol., QP
Head GNP Design & Manufacture
Justin Barry is a biopharmaceutical industry executive with extensive experience in setting up and leading manufacturing and quality operations. Prior to joining Midatech, he led the Spanish operations for Genentech where he was first responsible for quality assurance and control and later set up a new manufacturing facility for Avastin®, one of the most successful biological drugs to date. Before that, Justin set up manufacturing facilities for the Wellcome foundation and GSK in Europe and the USA. At GSK, he also held executive positions in quality assurance and control.
Dr Jan Mous, PhD
Chief Operating Officer
Dr Jan Mous is a biopharmaceutical industry executive who has led several successful biotechnology companies. Before joining Midatech, Dr. Mous was CEO of IntegraGen SA, a global biotech company based in France, which focused on next generation molecular diagnostics. Prior to that, he was CSO and executive board member of Lion Biosciences AG, co-leading the company in what was one of the most successful German biotech IPOs.
Dr Mous started his career in the biopharmaceutical industry at Hoffmann-La Roche where his last position was global head of Genomics and Proteomics. At Midatech, Dr Mous also chairs the Portfolio Management Board (PMB), which directs Midatech’s development projects.
Storme Moore-Thornicroft, MBA
Vice President, Corporate Development and Company Secretary
Storme Moore-Thornicroft is a co-founder of Midatech Ltd. She has over 15 years of biotech industry experience and has held senior positions in several biotech companies where she assisted in their formations, raised grants and equity capital and led organizational development activities. Previously she gained significant experience in the management of intellectual property and technology transfer at University College London.